Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
0(0%)
Results Posted
100%(13 trials)

Phase Distribution

Ph phase_1
2
15%
Ph phase_2
3
23%
Ph phase_3
8
62%

Phase Distribution

2

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
2(15.4%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
8(61.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(13)

Detailed Status

Completed13

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (15.4%)
Phase 23 (23.1%)
Phase 38 (61.5%)

Trials by Status

completed13100%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_3

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

NCT03537651
completedphase_3

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

NCT02565914
completedphase_2

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

NCT03912233
completedphase_1

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

NCT03768089
completedphase_1

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT03537651Phase 3

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Completed
NCT02565914Phase 3

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Completed
NCT03912233Phase 2

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Completed
NCT03768089Phase 1

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Completed
NCT03227471Phase 1

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Completed
NCT04105972Phase 3

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Completed
NCT04058353Phase 3

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Completed
NCT03224351Phase 2

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Completed
NCT02951195Phase 2

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Completed
NCT02953314Phase 3

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Completed
NCT03559062Phase 3

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Completed
NCT03525548Phase 3

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Completed
NCT03460990Phase 3

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13